Evidence map›Paper›PMID 42334675›Full record

ArticleDiscover oncology2026

Combination of p-STAT5, CRLF2 and copy number alterations as a potential indicator of a high-risk subgroup of acute lymphoblastic leukemia.

Eman O Rasekh, Maha Saleh, Marwa Hanafy, Shimaa Basha, Abdallah M Almuslimani, Youssef Madney, Raafat Abd El-Fattah, Azza M Kamel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eman O RasekhClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt. emorasekh@hotmail.com.
Maha SalehClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt.
Marwa HanafyClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt.
Shimaa BashaClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt.
Abdallah M AlmuslimaniClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt.
Youssef MadneyPediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Raafat Abd El-FattahMedical Oncology Department, NCI, Cairo University, Cairo, Egypt.
Azza M KamelClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Einy Street, P.O. Box 11796, Cairo, Egypt.

Funding

Science and Technology Development Fund 28921
6 · The paper itself

Abstract

purposeSignal transduction and transcription activation5 (STAT5) drives leukemic cell survival and treatment resistance in acute lymphoblastic leukemia (ALL), linking its activation to poor prognosis and highlighting it as an important biomarker and therapeutic target. We hypothesized that integrating STAT activation, cytokine receptor-like factor2 (CRLF2) overexpression, and copy number alterations (CNAs) affecting B-cell differentiation, cell-cycle control, and proliferation could define a high-risk ALL subtype, possibly including Philadelphia (Ph) like ALL.

methodsThe study included 115 precursor-B-ALL patients, comprising 88 (76.5%) children and 27 (23.5%) adults, 66 males (57.4%) and 49 females (42.6%). Expressions of p-STAT3, p-STAT5, and CRLF2 were assessed by flow cytometry. Forty patients, including 29 with positive marker expression, of whom 18 lacked any of the recurrent genetic translocations, were further tested for CNAs by Multiplex Ligation-dependent Probe Amplification (MLPA).

resultsp-STAT3, p-STAT5, and/or CRLF2 were expressed in 36 (31.3%) patients. p-STAT3 was positive in 6 (5.2%) patients, p-STAT5 in 27 (23.4%) patients, and CRLF2 overexpression was detected in 15 (13.04%) patients. Thirty/forty patients (75%) had one or more CNAs abnormalities, including deletions or duplications. p-STAT5 was detected in 6/7 (85.7%) patients with IKZF1 deletion. Higher day 42 MRD was significantly associated with IKZF1 deletion (p = 0.04). Adult patients with positive p-STAT3, p-STAT5, and/or CRLF2 overexpression had shorter overall survival (P < 0.01) and disease-free survival (P < 0.001).

conclusionThe expression of p-STAT5 and/or CRLF2 is probably associated with dismal prognosis in adults. A combined assessment of CRLF2, p-STAT5, and CNAs might identify a high-risk subset of ALL, potentially encompassing Ph-like ALL.

Indexed as

ALLCNAsCRLF2Flow cytometryp-STAT3p-STAT5

Identifiers

PMID42334675
PMCPMC13291284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.